HK1218709A1 - 新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法 - Google Patents

新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法 Download PDF

Info

Publication number
HK1218709A1
HK1218709A1 HK16106053.3A HK16106053A HK1218709A1 HK 1218709 A1 HK1218709 A1 HK 1218709A1 HK 16106053 A HK16106053 A HK 16106053A HK 1218709 A1 HK1218709 A1 HK 1218709A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
radical
compound
cancer
group
Prior art date
Application number
HK16106053.3A
Other languages
English (en)
Chinese (zh)
Inventor
梅利莎．
梅利莎．L．菲谢尔
．菲謝爾
帕特里克．托马斯．贡宁
帕特里克．托馬斯．貢寧
西纳．哈夫特舍纳里
西納．哈夫特舍納里
布伦特．戴维．乔治．帕盖
布倫特．戴維．喬治．帕蓋
塞谬尔．韦斯
塞謬爾．韋斯
赫马．阿蒂．卢奇曼
赫馬．阿蒂．盧奇曼
Original Assignee
多伦多大学管理委员会
Uti Limited Partnership
Indiana University Research And Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 多伦多大学管理委员会, Uti Limited Partnership, Indiana University Research And Technology Corporation filed Critical 多伦多大学管理委员会
Publication of HK1218709A1 publication Critical patent/HK1218709A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
HK16106053.3A 2012-05-25 2013-05-24 新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法 HK1218709A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651757P 2012-05-25 2012-05-25
US61/651,757 2012-05-25
PCT/US2013/042689 WO2013177534A2 (en) 2012-05-25 2013-05-24 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Publications (1)

Publication Number Publication Date
HK1218709A1 true HK1218709A1 (zh) 2017-03-10

Family

ID=49624538

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106053.3A HK1218709A1 (zh) 2012-05-25 2013-05-24 新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法

Country Status (9)

Country Link
US (3) US9650399B2 (enExample)
EP (1) EP2854819B1 (enExample)
JP (2) JP6290871B2 (enExample)
CN (2) CN110003104A (enExample)
BR (1) BR112014029439A2 (enExample)
CA (1) CA2874057A1 (enExample)
HK (1) HK1218709A1 (enExample)
RU (1) RU2641903C2 (enExample)
WO (1) WO2013177534A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153495A2 (en) 2013-03-22 2014-09-25 University Of Hawaii Novel stat3 inhibitors
JP6594908B2 (ja) * 2014-05-30 2019-10-23 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント スルホンアミド化合物およびそのｓｔａｔ５阻害剤としての使用
JP2020505457A (ja) * 2017-01-23 2020-02-20 ユニヴァーシティ オブ ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ ２−アリールスルホンアミド−Ｎ−アリールアセトアミド誘導体化Ｓｔａｔ３
CA3124267A1 (en) * 2018-12-21 2020-06-25 The Governing Council Of The University Of Toronto New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
TWI875749B (zh) 2019-04-05 2025-03-11 美商凱麥拉醫療公司 Stat降解劑及其用途
EP4041241A4 (en) 2019-09-27 2023-09-06 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSIS AND ASSOCIATED CONDITIONS
EP4114371A4 (en) * 2020-03-05 2024-04-17 Centessa Pharmaceuticals (UK) Limited ALPHA-SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF
EP4114377A4 (en) * 2020-03-05 2024-04-24 Centessa Pharmaceuticals (UK) Limited STAT INHIBITORY COMPOUNDS AND COMPOSITIONS
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN112941036B (zh) * 2021-02-08 2023-06-09 吉林惠康生物药业有限公司 一种提高狂犬病毒在人二倍体细胞中复制水平的方法
CN114751927B (zh) * 2022-03-08 2023-10-31 中山大学 一种硼酸化合物、制备方法及用途
CN118994047A (zh) * 2024-08-13 2024-11-22 中国药科大学 一种水杨醛衍生物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2548152C (en) * 2003-12-11 2013-09-10 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
AU2007234455B2 (en) * 2006-03-31 2012-10-04 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US7960434B2 (en) 2006-05-19 2011-06-14 University Of South Florida Small molecule inhibitors of STAT3 with anti-tumor activity
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
ES2622575T3 (es) * 2008-07-10 2017-07-06 General Incorporated Association Pharma Valley Project Supporting Organization Inhibidor de STAT3 que contiene un derivado de quinolincarboxamida como ingrediente activo
CA2757912A1 (en) 2009-04-06 2010-10-14 University Of Central Florida Research Foundation, Inc. Compounds that suppress cancer cells and exhibit antitumor activity
JP2013537535A (ja) * 2010-08-02 2013-10-03 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド Ｓｔａｔタンパク質の阻害剤としての、置換２−ヒドロキシ−４−（２−（フェニルスルホンアミド）アセトアミド）安息香酸類似体
WO2014153495A2 (en) * 2013-03-22 2014-09-25 University Of Hawaii Novel stat3 inhibitors

Also Published As

Publication number Publication date
CN105120854A (zh) 2015-12-02
RU2014152697A (ru) 2016-07-20
CN105120854B (zh) 2019-04-09
JP2018109017A (ja) 2018-07-12
US20150158894A1 (en) 2015-06-11
RU2641903C2 (ru) 2018-01-23
JP6290871B2 (ja) 2018-03-07
EP2854819A4 (en) 2016-06-15
CA2874057A1 (en) 2013-11-28
BR112014029439A2 (pt) 2017-06-27
WO2013177534A3 (en) 2015-05-28
EP2854819A2 (en) 2015-04-08
CN110003104A (zh) 2019-07-12
JP6543366B2 (ja) 2019-07-10
US9650399B2 (en) 2017-05-16
JP2015522551A (ja) 2015-08-06
EP2854819B1 (en) 2020-01-15
US10377780B2 (en) 2019-08-13
US20190382422A1 (en) 2019-12-19
WO2013177534A2 (en) 2013-11-28
US20170267704A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
JP6543366B2 (ja) 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法
KR102288648B1 (ko) 히스톤 데메틸라제 억제제로서의 치환된 (e)-n′-(1-페닐에틸리덴)벤조하이드라지드 동족체
CN105008351B (zh) Cdc7抑制剂
US10954258B2 (en) STAT3 dimerization inhibitors
CN110898067A (zh) 癌症治疗方法
HRP20031081A2 (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
CN110198938A (zh) 作为蛋白质聚集调节剂的双-杂芳基衍生物
WO2016155653A1 (zh) 轴手性异构体及其制备方法和制药用途
CN108409663A (zh) 微管抑制剂及其制备方法和用途
AU2015241177B2 (en) Histone acetyltransferase activators and uses thereof
JP2022515248A (ja) 新規なサリチル酸誘導体、その医薬的に許容される塩、その組成物及びその使用方法
US8895746B2 (en) Compounds that suppress cancer cells and exhibit antitumor activity
US11896589B2 (en) Diazinyl amino acridines and medical uses thereof
KR20120090034A (ko) 이소폼 선택성 포스포리파제 d 저해제
HK40063807A (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
WO2025126129A1 (en) Compounds with antitumor activity directed at the hippo pathway
JP2022547426A (ja) β－カテニン／ＴＣＦ４相互作用のモジュレーターとしての複素環化合物
JP2015163602A (ja) ［（４−ヒドロキシ−２−オキソ−１，２，５，６−テトラヒドロ−３−ピリジニル）カルボニル］グリシン化合物の結晶形及びそれらの製造方法